LYFE Sciences · Project HERA
Variant Interpretation · Classification Report
Generated: 2026-11-16
Case ID: NM_007294.4_c.4253T_C_20261116_184911
Framework: ACMG/AMP 2015 with ENIGMA Table 3 adaptations
Variant classification summary

NM_007294.4:c.4253T>C

BRCA1  · NP_009225.1:p.(Leu1418Ser)  · NM_007294.4
GRCh37: chr17:41234525 A>G  ·  GRCh38: chr17:43082508 A>G
Gene: BRCA1 Transcript: NM_007294.4
Final call
VUS
BP4 supporting
All criteria require review: For research and educational purposes only.
Gene
BRCA1
Transcript
NM_007294.4
Protein
NP_009225.1:p.(Leu1418Ser)
gnomAD AF
6.195057583060235e-07 (v4.1)
ClinVar
Uncertain significance
OncoKB
Unknown Oncogenic Effect
Interpretation summary
Generated evidence synthesis
1
VUS: BP4 supporting is met because BayesDel 0.0666657 and SpliceAI 0.01 satisfy the ENIGMA no-impact thresholds.
Final determination: Under ENIGMA BRCA1 VCEP Table 3, one Supporting benign criterion alone does not satisfy any benign or likely benign rule, while no pathogenic combination is met; the resulting call is VUS.
ACMG/AMP criteria review
Criteria shown when status is available
All criteria require review: For research and educational purposes only.
Criterion Status Rationale Evidence used
PVS1 N/A Not applicable: c.4253T>C is a missense variant, whereas the ENIGMA PVS1 rule applies to null variants such as nonsense, frameshift, canonical splice-site, initiation-codon, or exon-loss variants.
cspec vcep_specifications_table4_v1_2_2024_11_18 vcep_specifications_v1_2_2024_11_18 vcep_appendices_v1_2_2024_11_18
PS1 Not met Not met: SpliceAI is 0.01, but no previously classified pathogenic variant producing the same Leu1418Ser substitution was identified.
cspec clinvar spliceai
PS2 N/A Not applicable: the ENIGMA VCEP says PS2 must not be used because de novo occurrences lack calibrated predictive value for BRCA1/2-related cancers.
cspec vcep_specifications_v1_2_2024_11_18
PS3 Not assessed Not assessed: ENIGMA Table 9 and ST4 contain no exact c.4253T>C functional-assay entry or calibrated PS3 assignment.
cspec vcep_specifications_table9_v1_2_2024_11_18 vcep_supplementarytables_v1_2_2024_11_18 vcep_specifications_v1_2_2024_11_18 vcep_appendices_v1_2_2024_11_18 vcep_humu_40_1557_s001
PS4 Not assessed Not assessed: no verified case-control counts, odds ratio, p-value, or confidence interval are available for c.4253T>C.
cspec PMID:23788249
PM1 N/A Not applicable: residue 1418 lies in the 1391-1424 coiled-coil domain, but ENIGMA explicitly marks PM1 not applicable and redirects this evidence to other criteria.
cspec vcep_appendices_v1_2_2024_11_18 hotspots
PM2 Not assessed Not assessed: the variant is absent from both required non-cancer gnomAD datasets, but the VCEP-required regional average read depth of at least 25 is unavailable.
cspec vcep_appendices_v1_2_2024_11_18 gnomad_v2 gnomad_v4
PM3 Not assessed Not assessed: no documented Fanconi Anemia phenotype, same-gene co-occurring pathogenic/likely pathogenic variant, or trans phase is available to meet the VCEP PM3 pathway.
cspec vcep_specifications_v1_2_2024_11_18
PM4 N/A Not applicable: Leu1418Ser is a single-residue substitution and causes no protein-length change from an in-frame indel or stop-loss variant.
cspec vcep_specifications_v1_2_2024_11_18
PM5 N/A Not applicable: PM5 is restricted to genomic PTC changes, whereas c.4253T>C is a missense substitution producing Leu1418Ser.
cspec vcep_specifications_table4_v1_2_2024_11_18 vcep_supplementarytables_v1_2_2024_11_18
PM6 N/A Not applicable: the ENIGMA VCEP says PM6 must not be used because unconfirmed de novo occurrences lack calibrated predictive value for BRCA1/2-related cancers.
cspec vcep_specifications_v1_2_2024_11_18
PP1 Not assessed Not assessed: no quantitative co-segregation LR for multiple affected relatives is available; the only located LR is clinical-history LR 1.47600089290012, not PP1 evidence.
cspec vcep_specifications_v1_2_2024_11_18 vcep_pmid_31853058_brca1_clinical_history_lr PMID:31853058
PP2 N/A Not applicable: ENIGMA states that missense variants are not a common mechanism of pathogenicity for BRCA1 and BRCA2.
cspec
PP3 Not met Not met: BayesDel 0.0666657 is below the VCEP PP3 threshold of ≥0.28 and SpliceAI 0.01 is below its ≥0.2 splice threshold.
cspec vcep_specifications_v1_2_2024_11_18 vcep_appendices_v1_2_2024_11_18 bayesdel spliceai
PP4 N/A Not applicable: Li et al. clinical-history LR 1.47600089290012 is below the PP4 supporting threshold of 2.08.
cspec vcep_pmid_31853058_brca1_clinical_history_lr PMID:31853058
PP5 N/A Not applicable: the ENIGMA BRCA1 VCEP explicitly states that PP5 should not be used.
cspec vcep_specifications_v1_2_2024_11_18
BA1 Not met Not met: the variant is absent from the specified non-cancer gnomAD datasets and the available all-comers AF is 6.19506e-07, far below the 0.001 BA1 threshold.
cspec vcep_appendices_v1_2_2024_11_18 gnomad_v2 gnomad_v4
BS1 Not met Not met: the variant is absent from the specified non-cancer gnomAD datasets and the available all-comers AF 6.19506e-07 is below the 0.00002 BS1 Supporting threshold.
cspec vcep_appendices_v1_2_2024_11_18 gnomad_v2 gnomad_v4
BS2 Not assessed Not assessed: no qualifying healthy-adult clinical observation or same-gene pathogenic co-occurrence is available, and gnomAD frequency data cannot supply BS2 points.
cspec vcep_appendices_v1_2_2024_11_18 gnomad_v4
BS3 Not assessed Not assessed: ENIGMA Table 9 and ST4 contain no exact c.4253T>C functional-assay entry or calibrated BS3 assignment.
cspec vcep_specifications_table9_v1_2_2024_11_18 vcep_supplementarytables_v1_2_2024_11_18 vcep_specifications_v1_2_2024_11_18 vcep_appendices_v1_2_2024_11_18 vcep_humu_40_1557_s001
BS4 Not assessed Not assessed: no quantitative non-segregation LR or affected-relative genotype data is available to meet the ENIGMA BS4 thresholds.
cspec vcep_specifications_v1_2_2024_11_18
BP1 Not met Not met: SpliceAI is 0.01, but Leu1418 lies inside the VCEP coiled-coil domain spanning residues 1391-1424.
cspec vcep_appendices_v1_2_2024_11_18 spliceai
BP2 N/A Not applicable: ENIGMA explicitly says BP2 is not to be used and is applied only in the context of BS2.
cspec vcep_specifications_v1_2_2024_11_18
BP3 N/A Not applicable: BP3 requires an in-frame deletion or insertion in a repetitive region, but c.4253T>C is a missense substitution.
cspec vcep_specifications_v1_2_2024_11_18
BP4 Met Met at Supporting: BayesDel 0.0666657 is ≤0.15 and SpliceAI max delta 0.01 is ≤0.1 for this coiled-coil missense variant.
cspec vcep_specifications_v1_2_2024_11_18 vcep_appendices_v1_2_2024_11_18 bayesdel spliceai
BP5 N/A Not applicable: Li et al. clinical-history LR 1.47600089290012 is above the BP5 supporting threshold of 0.48.
cspec vcep_pmid_31853058_brca1_clinical_history_lr PMID:31853058
BP6 N/A Not applicable: the ENIGMA BRCA1 VCEP explicitly marks BP6 as not for use.
cspec vcep_specifications_v1_2_2024_11_18
BP7 N/A Not applicable: the VCEP BP7 paths cover silent or intronic variants, whereas this variant is missense.
cspec vcep_specifications_v1_2_2024_11_18 vcep_appendices_v1_2_2024_11_18
Disclaimer: The content and results provided by LYFE Sciences are for research and educational purposes only and must not be used as a substitute for professional medical judgment, diagnosis, or treatment. Always consult a qualified healthcare professional before making any clinical decisions.